Leukemia, Lymphocytic Clinical Trials

15 recruitingLast updated: June 18, 2026

There are 15 actively recruiting leukemia, lymphocytic clinical trials across 30 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Houston, Texas, United States, Bethesda, Maryland, United States, Eugene, Oregon, United States. Updated daily from ClinicalTrials.gov.


Leukemia, Lymphocytic Trials at a Glance

15 actively recruiting trials for leukemia, lymphocytic are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Houston, Bethesda, and Eugene. Lead sponsors running leukemia, lymphocytic studies include National Cancer Institute (NCI), Janssen Research & Development, LLC, and Eli Lilly and Company.

Browse leukemia, lymphocytic trials by phase

Treatments under study

About Leukemia, Lymphocytic Clinical Trials

Looking for clinical trials for Leukemia, Lymphocytic? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukemia, Lymphocytic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukemia, Lymphocytic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 3

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.737 enrolled143 locationsNCT05254743
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting

A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC60 enrolled1 locationNCT07602088
Recruiting

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Cilag S.A.S.180 enrolled1 locationNCT06299540
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled74 locationsNCT05963074
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled54 locationsNCT05947851
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Lymphoproliferative DisordersNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Dana-Farber Cancer Institute1,500 enrolled1 locationNCT00131014
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 1Phase 2

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic
Juno Therapeutics, a Subsidiary of Celgene320 enrolled86 locationsNCT03331198
Recruiting
Phase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting

Family Study of Lymphoproliferative Disorders

Multiple MyelomaLymphoma, Non-HodgkinLymphoma, B-Cell+2 more
Mayo Clinic3,000 enrolled1 locationNCT00626496
Recruiting
Phase 2

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Lymphoma, NonhodgkinLeukemia, Lymphocytic
Chi Kong Li20 enrolled1 locationNCT06462248
Recruiting

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Leukemia, Lymphocytic, Chronic, B-Cell
Institut Paoli-Calmettes4,200 enrolled1 locationNCT02869529